The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience

References

• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. doi:10.1016/S0140-6736(20)30045-3
   PubMed Web of Science ®Google Scholar
• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - A systematic Review and meta-analysis. PLoS One. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
   PubMed Web of Science ®Google Scholar
• Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14(6):615–631. doi:10.1016/0891-5849(93)90143-I
   PubMed Web of Science ®Google Scholar
• de Cosmo S, Viazzi F, Pacilli A, et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(11):1921–1929. doi:10.2215/CJN.03140315
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413. doi:10.1681/ASN.2008010080
   PubMed Web of Science ®Google Scholar
• Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–146. doi:10.1053/j.ajkd.2012.07.021
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15(1):1–12. doi:10.1186/1471-2369-15-122
   PubMed Web of Science ®Google Scholar
• Pizarro MH, Santos DC, Barros BSV, De Melo LGN, Gomes MB. Serum uric acid and renal function in patients with type 1 diabetes: a nationwide study in Brazil. Diabetol Metab Syndr. 2018;10(1):22. doi:10.1186/s13098-018-0324-7
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71(3):362–370. doi:10.1053/j.ajkd.2017.08.017
   PubMed Web of Science ®Google Scholar
• Bartáková V, Kuricová K, Pácal L, et al. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus. J Diabetes Complications. 2016;30(7):1300–1307. doi:10.1016/j.jdiacomp.2016.06.002
   PubMed Web of Science ®Google Scholar
• Chang Y-H, Lei -C-C, Lin K-C, Chang D-M, Hsieh C-H, Lee Y-J. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab Res Rev. 2016;32(6):557–564. doi:10.1002/dmrr.2768
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–650. doi:10.1053/j.ajkd.2004.06.006
   PubMed Web of Science ®Google Scholar
• Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease - 25-year follow-up. Arch Intern Med. 2009;169(4):342–350. doi:10.1001/archinternmed.2008.605
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, Kalaitzidis R, Liamis G. Uric acid and incident chronic kidney disease in dyslipidemic individuals. Curr Med Res Opin. 2018;34(7):1193–1199. doi:10.1080/03007995.2017.1372157
   PubMed Web of Science ®Google Scholar
• Takae K, Nagata M, Hata J, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese Community– the Hisayama Study. Circ J. 2016;80(8):1857–1862. doi:10.1253/circj.CJ-16-0030
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513. doi:10.1056/NEJMoa1915833
   PubMed Web of Science ®Google Scholar
• Afkarian M, Polsky S, Parsa A, et al. Preventing Early Renal Loss in Diabetes (PERL) study: a randomized double-blinded trial of allopurinoldrationale, design, and baseline data. Diabetes Care. 2019;42(8):1454–1463. doi:10.2337/dc19-0342
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Chen C-H, Deng S-T, et al. Allopurinol Use and risk of fatal hypersensitivity reactions. JAMA Intern Med. 2015;175(9):1550. doi:10.1001/jamainternmed.2015.3536
   PubMed Web of Science ®Google Scholar
• Frey N, Jossi J, Bodmer M, et al. The epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–1247. doi:10.1016/j.jid.2017.01.031
   PubMed Web of Science ®Google Scholar
• Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–191. doi:10.1097/BOR.0000000000000028
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017;8(5):555–560. doi:10.1016/j.jare.2017.05.001
   PubMed Web of Science ®Google Scholar
• Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67(1):74–82. doi:10.1016/0002-9343(79)90076-7
   PubMed Web of Science ®Google Scholar
• Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017;21(2):182–192. doi:10.1007/s10157-016-1288-2
   PubMed Web of Science ®Google Scholar
• Kohagura K, Tana T, Higa A, et al. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res. 2016;39(8):593–597. doi:10.1038/hr.2016.37
   PubMed Web of Science ®Google Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239–247. doi:10.1053/j.ajkd.2007.05.013
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796–803. doi:10.1053/j.ajkd.2008.12.021
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679–687.e1. doi:10.1016/j.amjmed.2011.09.033
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43(4):347–352. doi:10.1016/j.exger.2008.01.006
   PubMed Web of Science ®Google Scholar
• Yu M-A, Sánchez-Lozada LG, Johnson RJ, Kang D-H. Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1. doi:10.1097/HJH.0b013e328337da1d
   PubMed Web of Science ®Google Scholar
• Choi Y, Yoon Y, Lee K, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197–3204. doi:10.1096/fj.13-247148
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim Y-G, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–1106. doi:10.1161/hy1101.092839
   PubMed Web of Science ®Google Scholar
• Alem MM. Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018;36(4):12432. doi:10.1111/1755-5922.12432
   PubMed Web of Science ®Google Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–413. doi:10.1093/ndt/gft378
   PubMed Web of Science ®Google Scholar
• Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16(1):58. doi:10.1186/s12882-015-0047-z
   PubMed Web of Science ®Google Scholar
• Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PLoS One. 2017;12(11):e0187550. doi:10.1371/journal.pone.0187550
   PubMed Web of Science ®Google Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a Randomized Trial. Am J Kidney Dis. 2018;72(6):798–810. doi:10.1053/j.ajkd.2018.06.028
   PubMed Web of Science ®Google Scholar
• Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–2503. doi:10.1056/NEJMoa1916624
   PubMed Web of Science ®Google Scholar
• Feig DI. Urate-lowering therapy and chronic kidney disease progression. N Engl J Med. 2020;382(26):2567–2568. doi:10.1056/NEJMe2015886
   PubMed Web of Science ®Google Scholar